Method of treating cancer with DLL4 antagonist and chemotherapeutic agent

ABSTRACT

The invention provides methods for treating various types of cancer/tumor by administering the combination of Dll4 antagonists, in particular, Dll4 antibodies and fragments thereof that specifically bind human Dll4, and chemotherapeutic agents. Such combination therapies exhibit synergistic effects compared to the treatment with either agent alone. Thus, the methods of the invention are particularly beneficial for cancer patients who have low tolerance to the side effects caused by high dosages required for the treatment by either agent alone, by being able to reduce effective dosages. Pharmaceutical compositions and kits containing Dll4 antagonists and chemotherapeutic agents are also provided.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. application Ser. No.12/823,680, filed Jun. 25, 2010, now U.S. Pat. No. 8,518,887, whichclaims the benefit under 35 U.S.C §119(e) of U.S. ProvisionalApplication Nos. 61/220,465, filed Jun. 25, 2009, and 61/301,881, filedFeb. 5, 2010, each of which are herein specifically incorporated byreference in their entirety.

SEQUENCE LISTING

This application includes an electronic sequence listing in a file named“435900-Sequence.txt”, created on Jul. 23, 2013 and containing 400,727bytes. The contents of the text file are herein incorporated byreference.

BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention relates to methods of treating cancers or tumors with adelta-like ligand 4 (Dll4) antagonist, in particular, human antibodiesor fragments thereof that specifically bind human Dll4, in combinationwith one or more chemotherapeutic agents, and pharmaceuticalcompositions comprising a Dll4 antagonist and a chemotherapeutic agent.

2. Description of Related Art

Dll4 is a member of the Delta family of Notch ligands which exhibitshighly selective expression by vascular endothelium (Shutter et al.,2000, Genes Develop. 14:1313-1318). Dll4 is a ligand for Notchreceptors, including Notch 1 and Notch 4. Dll4 antagonists are usefulfor inhibiting tumor growth in various cancers. The nucleic acid andamino acid sequences for human Dll4 (hDll4) are shown in SEQ ID NOS:1and 2, respectively. Antibodies specific for human Dll4 and cancer/tumortreatment using Dll4 antibodies are disclosed in international patentapplication publications WO 2007/143689, WO 2008/042236, and WO2007/070671.

Chemotherapeutic agents are widely used for the treatment of cancer bothalone and in combination with surgery and/or radiation therapy.Combination therapies using a Dll4 antagonist and chemotherapeuticagents are disclosed in US patent application publications US2008/0014196 and US 2008/0107648.

BRIEF SUMMARY OF THE INVENTION

In a first aspect, the invention features a method of treating cancer ina subject in need thereof, comprising administering to the subject aDll4 antagonist in combination with a chemotherapeutic agent, whereinthe cancer is treated. The subject to be treated by the method of theinvention may include any mammalian species, but preferably humanssuffering from cancer.

The combination therapies of the present invention are particularlyuseful in Dll4-associated or Dll4-mediated condition or disease, whichis affected directly or indirectly by modulation of Dll4 activity. Morespecifically, since Dll4 is now shown to be involved in blood vesselgrowth and development, inhibiting or reducing Dll4-mediated bloodvessel growth or development or maturation using Dll4 antagonists, is aneffective treatment for cancer/tumor that requires sufficient bloodsupply for its growth and survival. Furthermore, combining Dll4antagonists with chemotherapeutic agents, including growth inhibitoryagents and other cytotoxic agents, synergistically enhances theiranti-cancer/anti-tumor effects. Cancers/tumors treatable by the methodsof the present invention include, but not by way of limitation, varioussolid malignancies, including ovarian cancer, uterus cancer, breastcancer, lung cancer, liver cancer, colorectal cancer, bladder cancer,renal cancer, prostate cancer, pancreatic cancer, stomach cancer, bonecancer, skin cancer, including melanoma, malignant soft tissue sarcoma,including, but not limited to, Ewing's sarcoma, rhabdomyosarcoma,leiomyosarcoma, adipocytic sarcoma, synovial sarcoma, malignant fibroushistiocytoma, epithelioid hemangioendothelioma, angiosarcoma,fibrosarcoma, and unclassified sarcomas, leukemia, including myeloma,and the like.

In one embodiment, the Dll4 antagonist is a Dll4 antibody or fragmentthereof (“Dll4 Ab”) that specifically binds Dll4 with high affinity andblocks the binding of Dll4 to the Notch receptors and/or neutralizesDll4 activities. The antibody may be polyclonal, monoclonal, chimeric,humanized, or a wholly human antibody. Preferably the antibody is afully human monoclonal antibody or monoclonal antibody fragment. Theantibody fragment may be a single chain antibody, an Fab, or an (Fab′)₂.

In another embodiment, the Dll4 Ab binds an epitope within theN-terminal domain (S27—R172), or the DSL domain (V173-C217), or theN-terminal-DSL domain (S27-C217), of Dll4 (SEQ ID NO:2). The Dll4 Ab tobe used in the methods of the invention is capable of binding human Dll4with high affinity and its dissociation constant (K_(D)) is about 500 pMor less, including about 300 pM or less, and including about 200 pM orless, as measured by surface plasmon resonance. For example, the Dll4 Abhas a heavy chain variable region (HCVR) comprising three heavy chainCDRs (H-CDRs) and a light chain variable region (LCVR) comprising threelight chain CDRs (L-CDRs), wherein the three heavy chain CDRs compriseCDR1, CDR2 and CDR3 of the amino acid sequence of SEQ ID NO:20 and thethree light chain CDRs comprise CDR1, CDR2 and CDR3 of the amino acidsequence of SEQ ID NO:28. In another embodiment, the heavy chain CDR1,CDR2 and CDR3 of the Dll4 Ab comprise the amino acid sequences of SEQ IDNOS: 22, 24 and 26, respectively. In another embodiment, the light chainCDR1, CDR2 and CDR3 of Dll4 Ab comprise the amino acid sequences of SEQID NOS:30, 32 and 34, respectively. In yet another embodiment, the Dll4Ab comprises heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ IDNO:22, 24 and 26, respectively, and light chain CDR1, CDR2 and CDR3sequences comprising SEQ ID NO:30, 32 and 34, respectively. In yetanother embodiment, the Dll4 Ab comprises a HCVR comprising the aminoacid sequence of SEQ ID NO:20 or 116, or a LCVR comprising the aminoacid sequence of SEQ ID NO:28 or 118. In yet another embodiment, theDll4 Ab comprises a HCVR/LCVR combination of SEQ ID NO:20/28 (REGN281)or 116/118 (REGN421).

In another embodiment, the Dll4 Ab comprises a heavy chainCDR1/CDR2/CDR3 combination and a light chain CDR1/CDR2/CDR3 combinationselected from: SEQ ID NO:6/8/10 and SEQ ID NO:14/16/18, respectively;SEQ ID NO:38/40/42 and SEQ ID NO:46/48/50, respectively; SEQ IDNO:54/56/58 and SEQ ID NO:62/64/66, respectively; SEQ ID NO:70/72/74 andSEQ ID NO:78/80/82, respectively; SEQ ID NO:86/88/90 and SEQ IDNO:94/96/98, respectively; and SEQ ID NO:102/104/106 and SEQ IDNO:110/112/114, respectively. In another embodiment, the Dll4 Abcomprises a HCVR comprising the amino acid sequence of SEQ ID NO:4, 36,52, 68, 84, or 100, or a LCVR comprising the amino acid sequence of SEQID NO:12, 44, 60, 76, 92, or 108. In yet another embodiment, the Dll4 Abcomprises a HCVR/LCVR combination selected from: SEQ ID NO:4/12(REGN279); SEQ ID NO:36/44 (REGN290); SEQ ID NO:52/60 (REGN306); SEQ IDNO:68/76 (REGN309); SEQ ID NO:84/92 (REGN310); and SEQ ID NO:100/108(REGN289).

The nucleotide sequences encoding the amino acid sequences of SEQ IDNOS:4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38,40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74,76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108,110, 112, 114, 116 and 118, are shown as SEQ ID NOS:3, 5, 7, 9, 11, 13,15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49,51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85,87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115 and117, respectively.

In one embodiment, the chemotherapeutic agent is an anti-mitotic agent,such as docetaxel, paclitaxel, and the like; a platinum-basedchemotherapeutic compound, such as cisplatin, carboplatin, iproplatin,oxaliplatin, and the like; or other conventional cytotoxic agent, suchas 5-fluorouracil (5-FU), capecitabine, irinotecan, leucovorin,gemcitabine; inhibitors of receptor tyrosine kinases and/orangiogenesis, such as ErbB inhibitors, RTK class III inhibitors, VEGFRinhibitors, and the like, and the Dll4 antagonist is a Dll4 antibody orfragment thereof as described above.

In a second aspect, the invention features a method of decreasing,reducing, or halting tumor growth in a subject in need thereof,comprising administering to the subject a Dll4 antagonist in combinationwith a chemotherapeutic agent, wherein tumor growth is decreased,reduced, or halted.

In a third aspect, the invention features a method of reducing theamount of a chemotherapeutic agent or a Dll4 antagonist necessary toachieve a desired therapeutic effect, compared to the administration ofeach agent alone, comprising administering the chemotherapeutic agentwith a Dll4 antagonist. In one embodiment, the amount of achemotherapeutic agent to achieve a desired therapeutic effect, such as,for example, halting or reducing tumor growth, is at least 10% less, atleast 20% less, at least 30% less, at least 40% less, or at least 50%less, in the presence of co-administered Dll4 antagonist, or vice versa.In general, it is desirable that the amount of a chemotherapeutic agentor the Dll4 antagonist can be reduced by about 30% to about 50%. Thus,the methods of the invention are particularly beneficial for cancerpatients who have low tolerance to the side effects caused by highdosages required for the treatment by either agent alone, by being ableto reduce effective dosages.

In a fourth aspect, the invention features a pharmaceutical compositioncomprising a Dll4 antagonist, a chemotherapeutic agent, and apharmaceutically acceptable carrier. In one embodiment, the Dll4antagonist is a Dll4 Ab or fragment thereof that specifically binds toDll4 with high affinity and neutralizes Dll4 activities, and thechemotherapeutic agent is any of those described herein.

In a fifth aspect, the invention features a kit comprising a containercomprising the pharmaceutical composition of the present invention, anda package insert with an instruction for use. In one embodiment, a kitmay comprise a container comprising therein an antibody orantigen-binding fragment thereof that specifically binds hDll4, one ormore additional containers comprising therein at least onechemotherapeutic agent selected from any of those described herein, anda package insert with an instruction for use.

Other objects and advantages will become apparent from a review of theensuing detailed description.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows the effects of Dll4 Ab in combination with cisplatin on thegrowth of human VMCub1 tumors (bladder carcinoma) implanted in SevereCombined Immunodeficiency (SCID) mice expressing humanized Dll4 protein(humanized Dll4 SCID mice) (Example 1). Human Fc control (♦ with solidline); REGN421 (Dll4 Ab) 2 mg/kg/injection (♦ with dashed line);cisplatin 0.5 mg/kg/injection (□); cisplatin 2 mg/kg/injection (▪);REGN421 2 mg/kg/injection+cisplatin 0.5 mg/kg/injection (◯); and REGN4212 mg/kg/injection+cisplatin 2 mg/kg/injection (●).

FIG. 2 shows the effects of Dll4 Ab in combination with cisplatin on thegrowth of human A549 tumors (non-small cell lung cancer) implanted inhumanized Dll4 SCID mice (Example 2). Human Fc control (●); REGN421 6mg/kg total dose (◯); cisplatin 5 mg/kg total dose (Δ); cisplatin 9mg/kg total dose (▴); REGN421 6 mg/kg+cisplatin 5 mg/kg total doses (◯);and REGN421 6 mg/kg+cisplatin 9 mg/kg total doses (♦).

FIG. 3 shows the effects of Dll4 Ab in combination with 5-FU on thegrowth of human HCT116 (colorectal carcinoma) implanted in humanizedDll4 SCID mice (Example 5). Human Fc control (●); REGN421 6 mg/kg totaldose (◯); 5-FU 45 mg/kg total dose (Δ); 5-FU 75 mg/kg total dose (▴);REGN421 6 mg/kg+5-FU 45 mg/kg total doses (⋄); and REGN421 6 mg/kg+5-FU75 mg/kg total doses (♦).

FIG. 4 shows the effects of Dll4 Ab in combination with Irinotecan onthe growth of human HCT116 tumors implanted in humanized Dll4 SCID mice(Example 6). Human Fc control (●); REGN421 6 mg/kg total dose (◯);irinotecan 22.5 mg/kg total dose (Δ); irinotecan 75 mg/kg total dose(▴); REGN421 6 mg/kg+irinotecan 22.5 mg/kg total doses (⋄); and REGN4216 mg/kg+irinotecan 75 mg/kg total doses (♦).

FIG. 5 shows the average (4 mice/group) fold changes of Hey1 geneexpression in Colo205 human colorectal tumor cells implanted inhumanized Dll4 SCID mice, with a single dose of REGN421 at 0.5, 5 or 15mg/kg, compared to the hFc at 15 mg/kg, measured at 5, 10, 24 and 72hours and 7 days post-dose.

DETAILED DESCRIPTION

Before the present methods are described, it is to be understood thatthis invention is not limited to particular methods, and experimentalconditions described, as such methods and conditions may vary. It isalso to be understood that the terminology used herein is for thepurpose of describing particular embodiments only, and is not intendedto be limiting, since the scope of the present invention will be limitedonly by the appended claims.

As used in this specification and the appended claims, the singularforms “a”, “an”, and “the” include plural references unless the contextclearly dictates otherwise. Thus for example, a reference to “a method”includes one or more methods, and/or steps of the type described hereinand/or which will become apparent to those persons skilled in the artupon reading this disclosure.

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this invention belongs. Although any methods andmaterials similar or equivalent to those described herein can be used inthe practice or testing of the present invention, the preferred methodsand materials are now described. All publications mentioned herein areincorporated herein by reference in their entirety.

Definitions

“Delta-like ligand 4”, “Dll4”, “hDll4” are used interchangeably to referto the protein encoded by the nucleic acid sequence of SEQ ID NO:1 andthe protein having the amino acid sequence of SEQ ID NO:2.

Dll4 antagonists include antibodies to Dll4 and fragments thereofcapable of blocking the binding of Dll4 to a Notch receptor (such asNotch1 and Notch4), fusion proteins comprising the extracellular domainof Dll4 fused to a multimerizing component, or fragments thereof (seefor example, US patent application publication nos. 2006/0134121 and2008/0107648), and peptides and peptibodies (see for example, US patentapplication publication no. 2003/0229023).

Unless specifically indicated otherwise, the term “antibody,” as usedherein, shall be understood to encompass antibody molecules comprisingtwo immunoglobulin heavy chains and two immunoglobulin light chains(i.e., “full antibody molecules”) as well as antigen-binding fragmentsthereof. The terms “antigen-binding portion” of an antibody,“antigen-binding fragment” of an antibody, and the like, as used herein,include any naturally occurring, enzymatically obtainable, synthetic, orgenetically engineered polypeptide or glycoprotein that specificallybinds an antigen to form a complex. Antigen-binding fragments of anantibody may be derived, e.g., from full antibody molecules using anysuitable standard techniques such as proteolytic digestion orrecombinant genetic engineering techniques involving the manipulationand expression of DNA encoding antibody variable and optionally constantdomains. Such DNA is known and/or is readily available from, e.g.,commercial sources, DNA libraries (including, e.g., phage-antibodylibraries), or can be synthesized. The DNA may be sequenced andmanipulated chemically or by using molecular biology techniques, forexample, to arrange one or more variable and/or constant domains into asuitable configuration, or to introduce codons, create cysteineresidues, modify, add or delete amino acids, etc.

Non-limiting examples of antigen-binding fragments include: (i) Fabfragments; (ii) F(ab′)₂ fragments; (iii) Fd fragments; (iv) Fvfragments; (v) single-chain Fv (scFv) molecules; (vi) dAb fragments; and(vii) minimal recognition units consisting of the amino acid residuesthat mimic the hypervariable region of an antibody (e.g., an isolatedcomplementarity determining region (CDR)). Other engineered molecules,such as diabodies, triabodies, tetrabodies and minibodies, are alsoencompassed within the expression “antigen-binding fragment,” as usedherein.

An antigen-binding fragment of an antibody will typically comprise atleast one variable domain. The variable domain may be of any size oramino acid composition and will generally comprise at least one CDRwhich is adjacent to or in frame with one or more framework sequences.In antigen-binding fragments having a V_(H) domain associated with aV_(L) domain, the V_(H) and V_(L) domains may be situated relative toone another in any suitable arrangement. For example, the variableregion may be dimeric and contain V_(H)-V_(H), V_(H)-V_(L) orV_(L)-V_(L) dimers. Alternatively, the antigen-binding fragment of anantibody may contain a monomeric V_(H) or V_(L) domain.

In certain embodiments, an antigen-binding fragment of an antibody maycontain at least one variable domain covalently linked to at least oneconstant domain. Non-limiting, exemplary configurations of variable andconstant domains that may be found within an antigen-binding fragment ofan antibody of the present invention include: (i) V_(H)-C_(H)1; (ii)V_(H)-C_(H)2; (iii) V_(H)-C_(H)3; (iv) V_(H)-C_(H)1-C_(H)2; (v)V_(H)-C_(H)1-C_(H)2-C_(H)3; (vi) V_(H)-C_(H)2-C_(H)3; (vii) V_(H)-C_(L);(viii) V_(L)-C_(H)1; (ix) V_(L)-C_(H)2; (x) V_(L)-C_(H)3; (xi)V_(L)-C_(H)1-C_(H)2; (xii) V_(L)-C_(H)1-C_(H)2-C_(H)3; (xiii)V_(L)-C_(H)2-C_(H)3; and (xiv) V_(L)-C_(L). In any configuration ofvariable and constant domains, including any of the exemplaryconfigurations listed above, the variable and constant domains may beeither directly linked to one another or may be linked by a full orpartial hinge or linker region. A hinge region may consist of at least 2(e.g., 5, 10, 15, 20, 40, 60 or more) amino acids which result in aflexible or semi-flexible linkage between adjacent variable and/orconstant domains in a single polypeptide molecule. Moreover, anantigen-binding fragment of an antibody of the present invention maycomprise a homo-dimer or hetero-dimer (or other multimer) of any of thevariable and constant domain configurations listed above in non-covalentassociation with one another and/or with one or more monomeric V_(H) orV_(L) domain (e.g., by disulfide bond(s)).

As with full antibody molecules, antigen-binding fragments may bemonospecific or multispecific (e.g., bispecific). A multispecificantigen-binding fragment of an antibody will typically comprise at leasttwo different variable domains, wherein each variable domain is capableof specifically binding to a separate antigen or to a different epitopeon the same antigen. Any multispecific antibody format, including theexemplary bispecific antibody formats disclosed herein, may be adaptedfor use in the context of an antigen-binding fragment of an antibody ofthe present invention using routine techniques available in the art.

The term “human antibody”, as used herein, is intended to includeantibodies having variable and constant regions derived from humangermline immunoglobulin sequences. The human mAbs of the invention mayinclude amino acid residues not encoded by human germline immunoglobulinsequences (e.g., mutations introduced by random or site-specificmutagenesis in vitro or by somatic mutation in vivo), for example in theCDRs and in particular CDR3. However, the term “human antibody”, as usedherein, is not intended to include mAbs in which CDR sequences derivedfrom the germline of another mammalian species (e.g., mouse), have beengrafted onto human FR sequences.

The fully-human anti-Dll4 antibodies disclosed herein may comprise oneor more amino acid substitutions, insertions and/or deletions in theframework and/or CDR regions of the heavy and light chain variabledomains as compared to the corresponding germline sequences. Suchmutations can be readily ascertained by comparing the amino acidsequences disclosed herein to germline sequences available from, forexample, public antibody sequence databases. The present inventionincludes antibodies, and antigen-binding fragments thereof, which arederived from any of the amino acid sequences disclosed herein, whereinone or more amino acids within one or more framework and/or CDR regionsare back-mutated to the corresponding germline residue(s) or to aconservative amino acid substitution (natural or non-natural) of thecorresponding germline residue(s) (such sequence changes are referred toherein as “germline back-mutations”). A person of ordinary skill in theart, starting with the heavy and light chain variable region sequencesdisclosed herein, can easily produce numerous antibodies andantigen-binding fragments which comprise one or more individual germlineback-mutations or combinations thereof. In certain embodiments, all ofthe framework and/or CDR residues within the V_(H) and/or V_(L) domainsare mutated back to the germline sequence. In other embodiments, onlycertain residues are mutated back to the germline sequence, e.g., onlythe mutated residues found within the first 8 amino acids of FR1 orwithin the last 8 amino acids of FR4, or only the mutated residues foundwithin CDR1, CDR2 or CDR3. Furthermore, the antibodies of the presentinvention may contain any combination of two or more germlineback-mutations within the framework and/or CDR regions, i.e., whereincertain individual residues are mutated back to the germline sequencewhile certain other residues that differ from the germline sequence aremaintained. Once obtained, antibodies and antigen-binding fragments thatcontain one or more germline back-mutations can be easily tested for oneor more desired property such as, improved binding specificity,increased binding affinity, improved or enhanced antagonistic oragonistic biological properties (as the case may be), reducedimmunogenicity, etc. Antibodies and antigen-binding fragments obtainedin this general manner are encompassed within the present invention.

The present invention also includes anti-Dll4 antibodies comprisingvariants of any of the HCVR, LCVR, and/or CDR amino acid sequencesdisclosed herein having one or more conservative substitutions. Forexample, the present invention includes anti-Dll4 antibodies havingHCVR, LCVR, and/or CDR amino acid sequences with, e.g., 10 or fewer, 8or fewer, 6 or fewer, 4 or fewer, 2 or 1, conservative amino acidsubstitution(s) relative to any of the HCVR, LCVR, and/or CDR amino acidsequences disclosed herein. In one embodiment, a HCVR comprises theamino acid sequence of SEQ ID NO:116 with 10 or fewer conservative aminoacid substitutions therein. In another embodiment, a HCVR comprises theamino acid sequence of SEQ ID NO:116 with 8 or fewer conservative aminoacid substitutions therein. In another embodiment, a HCVR comprises theamino acid sequence of SEQ ID NO:116 with 6 or fewer conservative aminoacid substitutions therein. In another embodiment, a HCVR comprises theamino acid sequence of SEQ ID NO:116 with 4 or fewer conservative aminoacid substitutions therein. In yet another embodiment, a HCVR comprisesthe amino acid sequence of SEQ ID NO:116 with 2 or 1 conservative aminoacid substitution(s) therein. In one embodiment, a LCVR comprises theamino acid sequence of SEQ ID NO:118 with 10 or fewer conservative aminoacid substitutions therein. In another embodiment, a LCVR comprises theamino acid sequence of SEQ ID NO:118 with 8 or fewer conservative aminoacid substitutions therein. In another embodiment, a LCVR comprises theamino acid sequence of SEQ ID NO:118 with 6 or fewer conservative aminoacid substitutions therein. In another embodiment, a LCVR comprises theamino acid sequence of SEQ ID NO:118 with 4 or fewer conservative aminoacid substitutions therein. In yet another embodiment, a LCVR comprisesthe amino acid sequence of SEQ ID NO:118 with 2 or 1 conservative aminoacid substitution(s) therein.

A “neutralizing” or “blocking” antibody, is intended to refer to anantibody whose binding to Dll4 results in inhibition of the biologicalactivity of Dll4. This inhibition of the biological activity of Dll4 canbe assessed by measuring one or more indicators of Dll4 biologicalactivity. These indicators of Dll4 biological activity can be assessedby one or more of several standard in vitro or in vivo assays known inthe art. For instance, the ability of an antibody to neutralize Dll4activity is assessed by inhibition of Dll4 binding to a Notch receptor.

The term “specifically binds,” or the like, means that an antibody orantigen-binding fragment thereof forms a complex with an antigen that isrelatively stable under physiologic conditions. Specific binding can becharacterized by an equilibrium dissociation constant of at least about1×10⁻⁶ M or less (e.g., a smaller K_(D) denotes a tighter binding).Methods for determining whether two molecules specifically bind are wellknown in the art and include, for example, equilibrium dialysis, surfaceplasmon resonance, and the like. An isolated antibody that specificallybinds hDll4 may, however, exhibit cross-reactivity to other antigenssuch as Dll4 molecules from other species. Moreover, multi-specificantibodies (e.g., bispecifics) that bind to hDll4 and one or moreadditional antigens are nonetheless considered antibodies that“specifically bind” hDll4, as used herein.

The term “K_(D)”, as used herein, is intended to refer to thedissociation constant of a particular antibody-antigen interaction.

The term “high affinity” antibody refers to those antibodies that bindDll4 with a K_(D) of less than about 500 pM, less than about 400 pM,less than about 300 pM, or less than about 200 pM, as measured bysurface plasmon resonance, e.g., BIACORE™ or solution-affinity ELISA,using, for example, monomeric Dll4; or a K_(D) of less than about 100pM, less than about 50 pM, or less than about 20 pM, as measured bysurface plasmon resonance, using, dimeric Dll4.

The term “surface plasmon resonance”, as used herein, refers to anoptical phenomenon that allows for the analysis of real-time biospecificinteractions by detection of alterations in protein concentrationswithin a biosensor matrix, for example using the BIACORE™ system(Pharmacia Biosensor AB, Uppsala, Sweden and Piscataway, N.J.).

The term “epitope” is a region of an antigen that is bound by anantibody. Epitopes may be defined as structural or functional.Functional epitopes are generally a subset of the structural epitopesand have those residues that directly contribute to the affinity of theinteraction. Epitopes may also be conformational, that is, composed ofnon-linear amino acids. In certain embodiments, epitopes may includedeterminants that are chemically active surface groupings of moleculessuch as amino acids, sugar side chains, phosphoryl groups, or sulfonylgroups, and, in certain embodiments, may have specific three-dimensionalstructural characteristics, and/or specific charge characteristics.

Chemotherapeutic agents are chemical compounds useful in the treatmentof cancer and include growth inhibitory agents or other cytotoxicagents. Examples of chemotherapeutic agents that can be used in thepresent methods include alkylating agents such as thiotepa andcyclosphosphamide (CYTOXAN®); alkyl sulfonates such as busulfan,improsulfan and piposulfan; aziridines such as benzodopa, carboquone,meturedopa, and uredopa; ethylenimines and methylamelamines includingaltretamine, triethylenemelamine, trietylenephosphoramide,triethylenethiophosphaoramide and trimethylolomelamine; nitrogenmustards such as chlorambucil, chlornaphazine, cholophosphamide,estramustine, ifosfamide, mechlorethamine, mechlorethamine oxidehydrochloride, melphalan, novembichin, phenesterine, prednimustine,trofosfamide, uracil mustard; nitrosureas such as carmustine,chlorozotocin, fotemustine, lomustine, nimustine, ranimustine;antibiotics such as aclacinomysins, actinomycin, authramycin, azaserine,bleomycins, cactinomycin, calicheamicin, carabicin, caminomycin,carzinophilin, chromomycins, dactinomycin, daunorubicin, detorubicin,6-diazo-5-oxo-L-norleucine, doxorubicin, epirubicin, esorubicin,idarubicin, marcellomycin, mitomycins, mycophenolic acid, nogalamycin,olivomycins, peplomycin, potfiromycin, puromycin, quelamycin,rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex,zinostatin, zorubicin; anti-metabolites such as methotrexate and 5-FU;folic acid analogues such as denopterin, methotrexate, pteropterin,trimetrexate; purine analogues such as fludarabine, 6-mercaptopurine,thiamiprine, thioguanine; pyrimidine analogues such as ancitabine,azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine,doxifluridine, enocitabine, floxuridine; androgens such as calusterone,dromostanolone propionate, epitiostanol, mepitiostane, testolactone;anti-adrenals such as aminoglutethimide, mitotane, trilostane; folicacid replenisher such as frolinic acid; aceglatone; aldophosphamideglycoside; aminolevulinic acid; amsacrine; bestrabucil; bisantrene;edatraxate; defofamine; demecolcine; diaziquone; elformithine;elliptinium acetate; etoglucid; gallium nitrate; hydroxyurea; lentinan;lonidamine; mitoguazone; mitoxantrone; mopidamol; nitracrine;pentostatin; phenamet; pirarubicin; podophyllinic acid;2-ethylhydrazide; procarbazine; PSK®; razoxane; sizofiran;spirogermanium; tenuazonic acid; triaziquone;2,2′,2″-trichlorotriethylamine; urethan; vindesine; dacarbazine;mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine;arabinoside (“Ara-C”); cyclophosphamide; thiotepa; members of taxoid ortaxane family, such as paclitaxel (TAXOL®, Bristol-Myers SquibbOncology, Princeton, N.J.), docetaxel (TAXOTERE®; Aventis Antony,France) and analogues thereof; chlorambucil; gemcitabine; 6-thioguanine;mercaptopurine; methotrexate; platinum analogues such as cisplatin andcarboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide;mitomycin C; mitoxantrone; vincristine; vinorelbine; navelbine;novantrone; teniposide; daunomycin; aminopterin; xeloda; ibandronate;CPT-11; topoisomerase inhibitor RFS 2000; difluoromethylornithine(DMFO); retinoic acid; esperamicins; capecitabine; inhibitors ofreceptor tyrosine kinases and/or angiogenesis, including sorafenib(NEXAVAR® by Bayer Pharmaceuticals Corp.), sunitinib (SUTENT® byPfizer), pazopanib (VOTRIENT™ by GlaxoSmithKline), toceranib (PALLADIA™by Pfizer), vandetanib (ZACTIMA™ by AstraZeneca), cediranib (RECENTIN®by AstraZeneca), regorafenib (BAY 73-4506 by Bayer), axitinib (AG013736by Pfizer), lestaurtinib (CEP-701 by Cephalon), erlotinib (TARCEVA® byGenentech), gefitinib (IRESSA™ by AstraZeneca), BIBW 2992 (TOVOK™ byBoehringer Ingelheim), lapatinib (TYKERB® by GlaxoSmithKline), neratinib(HKI-272 by Wyeth/Pfizer), and the like, and pharmaceutically acceptablesalts, acids or derivatives of any of the above. Also included in thisdefinition are anti-hormonal agents that act to regulate or inhibithormone action on tumors such as anti-estrogens including for exampletamoxifen, raloxifene, aromatase inhibiting 4(5)-imidazoles,4-hydroxytamoxifen, trioxifene, keoxifene, LY 117018, onapristone, andtoremifene (FARESTON®); and anti-androgens such as flutamide,nilutamide, bicalutamide, leuprolide, and goserelin; andpharmaceutically acceptable salts, acids or derivatives of any of theabove. Other conventional cytotoxic chemical compounds as thosedisclosed in Wiemann et al., 1985, in Medical Oncology (Calabresi etal., eds.), Chapter 10, McMillan Publishing, are also applicable to themethods of the present invention.

The term “growth inhibitory agents” refers to a compound or compositionwhich inhibits growth of a cell, especially a cancer cell either invitro or in vivo. Examples of growth inhibitory agents include agentsthat block cell cycle progression (at a place other than S phase), suchas agents that induce G1 arrest and M-phase arrest. Classical M-phaseblockers include the vincas (vincristine and vinblastine), taxane familymembers, including, but not limited to, paclitaxel (TAXOL®), docetaxel(TAXOTERE®), and analogues thereof (e.g., XRP9881 and XRP6258; see Ojimaet al., Curr Opin Investig Drugs 4:737, 2003), and topoisomeraseinhibitors, such as irinotecan, topotecan, camptothecin, lamellarin D,doxorubicin, epirubicin, daunorubicin, etoposide, and bleomycin. Thoseagents that arrest G1 also spill over into S-phase arrest, for example,DNA alkylating agents, such as tamoxifen, prednisone, dacarbazine,mechlorethamine, cisplatin, methotrexate, 5-FU, and ara-C.

General Description

The present invention is based on the findings that co-administration ofa Dll4 antagonist, for example, a Dll4 antibody or fragment thereof thatspecifically binds Dll4 and blocks Dll4 activities, with achemotherapeutic agent, for example, cisplatin or docetaxel, results ingreater inhibition of tumor growth than either single agent. For adescription of fully human Dll4 Ab, including recombinant human Dll4 Ab,see international patent application publication no. WO 2008/076379.

Methods of Preparing Dll4 Ab

Methods for preparing antibodies are known to the art. See, for example,Kohler & Milstein (1975) Nature 256:495-497; Harlow & Lane (1988)Antibodies: a Laboratory Manual, Cold Spring Harbor Lab., Cold SpringHarbor, N.Y.). Antibodies that are isolated from organisms other thanhumans, such as mice, rats, rabbits, cows, can be made more human-likethrough chimerization or humanization.

“Humanized” or chimeric forms of non-human (e.g., murine) antibodies areimmunoglobulins, immunoglobulin chains or fragments thereof (such as Fv,Fab, Fab′, F(ab′)₂ or other antigen-binding subsequences of antibodies)that contain minimal sequences required for antigen binding derived fromnon-human immunoglobulin. They have the same or similar bindingspecificity and affinity as a mouse or other nonhuman antibody thatprovides the starting material for construction of a chimeric orhumanized antibody. Chimeric antibodies are antibodies whose light andheavy chain genes have been constructed, typically by geneticengineering, from immunoglobulin gene segments belonging to differentspecies. For example, the variable (V) segments of the genes from amouse monoclonal antibody may be joined to human constant (C) segments,such as IgG1 and IgG4. A typical chimeric antibody is thus a hybridprotein consisting of the V or antigen-binding domain from a mouseantibody and the C or effector domain from a human antibody. Humanizedantibodies have variable region framework residues substantially from ahuman antibody (termed an acceptor antibody) and complementaritydetermining regions (CDR regions) substantially from a mouse antibody,(referred to as the donor immunoglobulin). See, Queen et al., Proc.Natl. Acad. Sci. USA 86:10029-10033 (1989) and international patentapplication publication no. WO 90/07861 and U.S. Pat. Nos. 5,693,762,5,693,761, 5,585,089, 5,530,101 and 5,225,539. The constant region(s),if present, are also substantially or entirely from a humanimmunoglobulin. The human variable domains are usually chosen from humanantibodies whose framework sequences exhibit a high degree of sequenceidentity with the murine variable region domains from which the CDRswere derived. The heavy and light chain variable region frameworkresidues can be derived from the same or different human antibodysequences. The human antibody sequences can be the sequences ofnaturally occurring human antibodies or can be consensus sequences ofseveral human antibodies. See international patent applicationpublication no. WO 92/22653. Certain amino acids from the human variableregion framework residues are selected for substitution based on theirpossible influence on CDR conformation and/or binding to antigen.Investigation of such possible influences may be performed by modeling,examination of the characteristics of the amino acids at particularlocations, or empirical observation of the effects of substitution ormutagenesis of particular amino acids. For example, when an amino aciddiffers between a murine variable region framework residue and aselected human variable region framework residue, the human frameworkamino acid should usually be substituted by the equivalent frameworkamino acid from the mouse antibody when it is reasonably expected thatthe amino acid: (1) noncovalently binds antigen directly; (2) isadjacent to a CDR region; (3) otherwise interacts with a CDR region(e.g., is within about 6 Å of a CDR region), or (4) participates in theV_(L)-V_(H) interface. Other candidates for substitution are acceptorhuman framework amino acids that are unusual for a human immunoglobulinat that position. These amino acids can be substituted with amino acidsfrom the equivalent position of the mouse donor antibody or from theequivalent positions of more typical human immunoglobulins. Othercandidates for substitution are acceptor human framework amino acidsthat are unusual for a human immunoglobulin at that position. Thevariable region frameworks of humanized immunoglobulins usually show atleast 85% sequence identity to a human variable region frameworksequence or consensus of such sequences.

Methods for generating human antibodies include, for example,VELOCIMMUNE™ (Regeneron Pharmaceuticals), XENOMOUSE™ technology(Abgenix), the “minilocus” approach, and phage display. The VELOCIMMUNE™technology (U.S. Pat. No. 6,596,541) encompasses a method of generatinga high specificity fully human antibody to a select antigen. Thistechnology involves generation of a transgenic mouse having a genomecomprising human heavy and light chain variable regions operably linkedto endogenous mouse constant region loci such that the mouse produces anantibody comprising a human variable region and a mouse constant regionin response to antigenic stimulation. The DNA encoding the variableregions of the heavy and light chains of the antibody are isolated andoperably linked to DNA encoding the human heavy and light chain constantregions. The DNA is then expressed in a cell capable of expressing thefully human antibody. In one embodiment, the cell is a CHO cell.

The XENOMOUSE™ technology (Green et al., 1994, Nature Genetics 7:13-21)generates a mouse having both human variable and constant regions fromboth the heavy chain and kappa light chain loci. In an alternativeapproach, others have utilized a ‘minilocus” approach in which anexogenous Ig locus is mimicked through inclusion of individual genesfrom the Ig locus (see, for example, U.S. Pat. No. 5,545,807). The DNAencoding the variable regions can be isolated with or without beingoperably linked to the DNA encoding the human heavy and light chainconstant region.

Alternatively, phage display or related display technologies can be usedto identify antibodies, antibody fragments, such as variable domains,and heteromeric Fab fragments that specifically bind to Dll4. (see, forexample, US patent application publication no. 2003/0229023).

Screening and selection of preferred immunoglobulins (antibodies) can beconducted by a variety of methods known to the art. Initial screeningfor the presence of monoclonal antibodies specific to Dll4 may beconducted through the use of ELISA-based methods or phage display, forexample. A secondary screen is preferably conducted to identify andselect a desired monoclonal antibody. Secondary screening may beconducted with any suitable method known to the art. One preferredmethod, termed “Biosensor Modification-Assisted Profiling” (“BiaMAP”) isdescribed in U.S. patent application publication no. 2004/101920. BiaMAPallows rapid identification of hybridoma clones producing monoclonalantibodies with desired characteristics. More specifically, monoclonalantibodies are sorted into distinct epitope-related groups based onevaluation of antibody:antigen interactions. Alternatively, ELISA-based,bead-based, or BIACORE®-based competition assays can be used to identifybinding pairs that bind different epitopes of Dll4 and thus are likelyto cooperate to bind the ligand with high affinity.

Methods of Administration

The present invention provides methods of treatment comprisingadministering to a subject an effective amount of a pharmaceuticalcomposition comprising a Dll4 antagonist, such as a Dll4 Ab, and achemotherapeutic agent, such as anti-mitotic agents, for example,docetaxel, paclitaxel, and the like (taxanes); platinum-basedchemotherapeutic compounds, such as cisplatin, carboplatin, iproplatin,oxaliplatin, and the like; pyrimidine analogue, such as 5-Fu,capecitabine (XELODA®, Roche), and the like; topoisomerase inhibitors,such as irinotecan, topotecan, camptothecin, lamellarin D, and the like;and/or adjuvants, such as leucovorin (folinic acid), and the like (fordetails, see the definition section above).

The Dll4 antagonist and the chemotherapeutic agent can beco-administered together or separately. Where separate dosageformulations are used, the Dll4 antagonist and the chemotherapeuticagent can be administered concurrently, or separately at staggeredtimes, i.e., sequentially.

Various delivery systems are known and can be used to administer thepharmaceutical composition of the invention, e.g., encapsulation inliposomes, microparticles, microcapsules, recombinant cells capable ofexpressing the mutant viruses, receptor mediated endocytosis (see, e.g.,Wu and Wu, 1987, J. Biol. Chem. 262:4429 4432). Methods of introductioninclude but are not limited to intradermal, intramuscular,intraperitoneal, intravenous, subcutaneous, intranasal, intraocular,epidural, and oral routes. The composition may be administered by anyroute, for example by infusion or bolus injection, by absorption throughepithelial or mucocutaneous linings (e.g., oral mucosa, rectal andintestinal mucosa, etc.) and may be administered together with otherbiologically active agents. Administration can be systemic or local.Administration can be acute or chronic (e.g., daily, weekly, monthly,etc.) or in combination with other agents. Pulmonary administration canalso be employed, for example, by use of an inhaler or nebulizer, andformulation with an aerosolizing agent.

With respect to subcutaneous delivery, a pen delivery device readily hasapplications in delivering a pharmaceutical composition of the presentinvention. Such a pen delivery device can be reusable or disposable. Areusable pen delivery device generally utilizes a replaceable cartridgethat contains a pharmaceutical composition. Once all of thepharmaceutical composition within the cartridge has been administeredand the cartridge is empty, the empty cartridge can readily be discardedand replaced with a new cartridge that contains the pharmaceuticalcomposition. The pen delivery device can then be reused. In a disposablepen delivery device, there is no replaceable cartridge. Rather, thedisposable pen delivery device comes prefilled with the pharmaceuticalcomposition held in a reservoir within the device. Once the reservoir isemptied of the pharmaceutical composition, the entire device isdiscarded.

Numerous reusable pen delivery devices have applications in thesubcutaneous delivery of a pharmaceutical composition of the presentinvention. Examples include, but certainly are not limited to AUTOPEN™(Owen Mumford, Inc., Woodstock, UK), DISETRONIC™ pen (Disetronic MedicalSystems, Burghdorf, Switzerland), HUMALOG MIX 75/25™ pen, HUMALOG™ pen,HUMALIN 70/30™ pen (Eli Lilly and Co., Indianapolis, Ind.), NOVOPEN™ I,II and III (Novo Nordisk, Copenhagen, Denmark), NOVOPEN JUNIOR™ (NovoNordisk, Copenhagen, Denmark), BD™ pen (Becton Dickinson, FranklinLakes, N.J.), OPTIPEN™, OPTIPEN PRO™, OPTIPEN STARLET™, and OPTICLIK™(sanofi-aventis, Frankfurt, Germany), to name only a few. Examples ofdisposable pen delivery devices having applications in subcutaneousdelivery of a pharmaceutical composition of the present inventioninclude, but certainly are not limited to the SOLOSTAR™ pen(sanofi-aventis), the FLEXPEN™ (Novo Nordisk), and the KWIKPEN™ (EliLilly).

In another embodiment, the active agent can be delivered in a vesicle,or a liposome (see Langer (1990) Science 249:1527-1533). In yet anotherembodiment, the active agent can be delivered in a controlled releasesystem. In one embodiment, a pump may be used (see Langer (1990) supra).In another embodiment, polymeric materials can be used (see Howard etal. (1989) J. Neurosurg. 71:105). In another embodiment where the activeagent of the invention is a nucleic acid encoding a protein, the nucleicacid can be administered in vivo to promote expression of its encodedprotein, by constructing it as part of an appropriate nucleic acidexpression vector and administering it so that it becomes intracellular,e.g., by use of a retroviral vector (see, for example, U.S. Pat. No.4,980,286), or by direct injection, or by use of microparticlebombardment (e.g., a gene gun; Biolistic, Dupont), or coating withlipids or cell-surface receptors or transfecting agents, or byadministering it in linkage to a homeobox-like peptide which is known toenter the nucleus (see e.g., Joliot et al., 1991, Proc. Natl. Acad. Sci.USA 88:1864-1868), etc. Alternatively, a nucleic acid can be introducedintracellularly and incorporated within host cell DNA for expression, byhomologous recombination.

In a specific embodiment, it may be desirable to administer thepharmaceutical compositions of the invention locally to the area in needof treatment; this may be achieved, for example, and not by way oflimitation, by local infusion during surgery, topical application, e.g.,by injection, by means of a catheter, or by means of an implant, saidimplant being of a porous, non-porous, or gelatinous material, includingmembranes, such as sialastic membranes, fibers, or commercial skinsubstitutes.

The amount of the active agent of the invention which will be effectivein the treatment of cancer/tumor can be determined by standard clinicaltechniques based on the present description. In addition, in vitroassays may optionally be employed to help identify optimal dosageranges. The precise dose to be employed in the formulation will alsodepend on the route of administration, and the seriousness of thecondition, and should be decided according to the judgment of thepractitioner and each subject's circumstances. However, suitable dosageranges for intravenous administration are generally about 0.2 to 30 mgof active compound per kilogram body weight. Suitable dosage ranges forintranasal administration are generally about 0.01 pg/kg body weight to1 mg/kg body weight. Effective doses may be extrapolated fromdose-response curves derived from in vitro or animal model test systems.

For systemic administration, a therapeutically effective dose can beestimated initially from in vitro assays. For example, a dose can beformulated in animal models to achieve a circulating concentration rangethat includes the IC₅₀ as determined in cell culture. Such informationcan be used to more accurately determine useful doses in humans. Initialdosages can also be estimated from in vivo data, e.g., animal models,using techniques that are well known in the art. One having ordinaryskill in the art could readily optimize administration to humans basedon animal data.

The dose may vary depending upon the age and the size (e.g., body weightor body surface area) of a subject to be administered, target disease,conditions, route of administration, and the like. For systemicadministration of Dll4 antagonists, in particular, for Dll4 antibodies,typical dosage ranges for intravenous administration are at a daily doseof about 0.01 to about 100 mg/kg of body weight, about 0.1 to about 50mg/kg, or about 0.2 to about 10 mg/kg. For subcutaneous administration,the antibodies can be administered at about 10 mg to about 500 mg, about20 mg to about 400 mg, about 30 mg to about 300 mg, or about 50 mg toabout 200 mg, at the antibody concentration of, at least, about 25mg/ml, about 50 mg/ml, about 75 mg/ml, about 100 mg/ml, about 125 mg/ml,about 150 mg/ml, about 175 mg/ml, about 200 mg/ml, or about 250 mg/ml,at least, 1 to 5 times per day, 1 to 5 times per week, or 1 to 5 timesper month. Alternatively, the antibodies can be initially administeredvia intravenous injection, followed by sequential subcutaneousadministration.

In general, chemotherapeutic agents are used intravenously or orally ata dose range of between 50 mg/m² and 5000 mg/m² per week, but the dosageranges vary depending on various factors, including the subject beingtreated, the subject's weight and age, the severity of the affliction,the manner of administration, the type of chemotherapeutic agent beingused, the judgment of the prescribing physician, and the like. Thetherapy may be repeated intermittently while symptoms are detectable oreven when they are not detectable. The duration of the treatment mayalso vary depending on the severity of the conditions treated as well astolerance levels of subjects for possible adverse effects, if any, andmay last as long as necessary or so long as the benefit outweighs anyadverse effect.

The dosage of each agent may be further adjusted in the combinationtherapy, where the amount of each agent necessary to achieve a desiredtherapeutic effect is reduced (i.e., exhibiting a synergistic effect),compared to the administration of either agent alone (see Examples 1 and2, infra).

Chemotherapeutic agents that can be used in the combination therapies ofthe invention also include those which are employed in well-knownchemotherapeutic regimens. For example, FOLFOX is a chemotherapeuticregimen for treating colorectal cancer (CRC) and is a combination of5-FU, folinic acid and oxaliplatin. FOLFIRI is another chemotherapeuticregimen for CRC and is a combination of 5-FU, folinic acid andirinotecan. XELOX is a second-line chemotherapeutic regimen for CRC andis a combination of capecitabine and oxaliplatin.

Further, the therapy with the combination of a chemotherapeutic agentand a Dll4 antagonist may be provided alone or in combination withadditional drugs, such as other anti-angiogenic agents, e.g., VEGFantagonists, including anti-VEGF antibodies (e.g., AVASTIN® byGenentech), VEGF-binding fusion proteins (e.g., aflibercept by RegeneronPharmaceuticals), and the like, and other therapeutic agents, such asanalgesics, anti-inflammatory agents, including non-steroidalanti-inflammatory drugs (NSAIDS), such as Cox-2 inhibitors, and thelike, so as to ameliorate and/or reduce the symptoms accompanying theunderlying cancer/tumor.

Metronomic Chemotherapies

Metronomic chemotherapy is emerging as an improved way of administeringchemotherapy. Traditional chemotherapy has been administered in singledoses or short courses of therapy as the highest dose possible withoutcausing life-threatening levels of toxicity, e.g., at the maximumtolerated dose (MTD). MTD therapy requires prolonged breaks of 2-3 weeksbetween successive cycles of therapy. Despite the number of suchchemotherapeutics and large number of clinical trials undertaken to testthem, progress has been modest in terms of curing or significantlyprolonging the lives of patients with cancer (Kerbel et al., 2004,Nature Reviews Cancer 4:423-436).

Metronomic chemotherapy refers to the frequent, even daily,administration of chemotherapeutics at doses significantly below theMTD, with no prolonged drug-free breaks. In addition to reduced acutetoxicity, the efficacy of metronomic chemotherapy may increase whenadministered in combination with specific anti-angiogenic drugs, such asinhibitors of VEGF (Kerbel et al., 2004, supra).

Accordingly, the present invention features a metronomic chemotherapyfor treating cancer in a subject in need thereof, comprisingadministering to the subject a Dll4 antagonist in combination with achemotherapeutic agent, wherein the cancer is treated. In a specificembodiment, the Dll4 antagonist and a chemotherapeutic agent may beadministered together or sequentially for a relatively short period oftime, for example, 1-12 weeks, followed by metronomic administration ofthe chemotherapeutic agent over a prolonged period of time, for example,6-24 months.

Pharmaceutical Compositions

The present invention provides pharmaceutical compositions comprising aDll4 antagonist, a chemotherapeutic agent, and a pharmaceuticallyacceptable carrier. The term “pharmaceutically acceptable” meansapproved by a regulatory agency of the Federal or a state government orlisted in the U.S. Pharmacopeia or other generally recognizedpharmacopeia for use in animals, and more particularly, in humans. Theterm “carrier” refers to a diluent, adjuvant, excipient, or vehicle withwhich the therapeutic is administered. Such pharmaceutical carriers canbe sterile liquids, such as water and oils, including those ofpetroleum, animal, vegetable or synthetic origin, such as peanut oil,soybean oil, mineral oil, sesame oil and the like. Suitablepharmaceutical excipients include starch, glucose, lactose, sucrose,gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerolmonostearate, talc, sodium chloride, dried skim milk, glycerol,propylene, glycol, water, ethanol and the like. The composition, ifdesired, can also contain minor amounts of wetting or emulsifyingagents, or pH buffering agents. These compositions can take the form ofsolutions, suspensions, emulsion, tablets, pills, capsules, powders,sustained-release formulations and the like. The composition can beformulated as a suppository, with traditional binders and carriers suchas triglycerides. Oral formulation can include standard carriers such aspharmaceutical grades of mannitol, lactose, starch, magnesium stearate,sodium saccharine, cellulose, magnesium carbonate, etc. Examples ofsuitable pharmaceutical carriers are described in “Remington'sPharmaceutical Sciences” by E.W. Martin.

In a preferred embodiment, the composition is formulated in accordancewith routine procedures as a pharmaceutical composition adapted forintravenous administration to human beings. Where necessary, thecomposition may also include a solubilizing agent and a local anestheticsuch as lidocaine to ease pain at the site of the injection. Where thecomposition is to be administered by infusion, it can be dispensed withan infusion bottle containing sterile pharmaceutical grade water orsaline. Where the composition is administered by injection, an ampouleof sterile water for injection or saline can be provided so that theingredients may be mixed prior to administration.

The active agents of the invention can be formulated as neutral or saltforms. Pharmaceutically acceptable salts include those formed with freeamino groups such as those derived from hydrochloric, phosphoric,acetic, oxalic, tartaric acids, etc., and those formed with freecarboxyl groups such as those derived from sodium, potassium, ammonium,calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylaminoethanol, histidine, procaine, etc.

A composition useful in practicing the methods of the invention may be aliquid comprising an agent of the invention in solution, in suspension,or both. The term “solution/suspension” refers to a liquid compositionwhere a first portion of the active agent is present in solution and asecond portion of the active agent is present in particulate form, insuspension in a liquid matrix. The liquid composition may be aqueous andalso includes a gel and an ointment forms.

An aqueous suspension or solution/suspension useful for practicing themethods of the invention may contain one or more polymers as suspendingagents. Useful polymers include water-soluble polymers such ascross-linked carboxyl-containing polymers. An aqueous suspension orsolution/suspension of the present invention is preferably viscous ormuco-adhesive, or even more preferably, both viscous and mucoadhesive.

Kits

The invention further provides an article of manufacturing or kit,comprising a packaging material, container and a pharmaceutical agentcontained within the container, wherein the pharmaceutical agentcomprises at least one Dll4 antagonist, such as Dll4 antibody, and atleast one chemotherapeutic agent, and wherein the packaging materialcomprises a label or package insert which indicates that the Dll4antagonist and chemotherapeutic agent can be used for treating cancer orreducing or halting tumor growth. In one embodiment, the Dll4 antagonistand the chemotherapeutic agent may be contained in separate containers;thus, the invention provides a kit comprising a container comprisingtherein an antibody or antigen-binding fragment thereof thatspecifically binds hDll4, and one or more additional containerscomprising therein at least one chemotherapeutic agent.

EXAMPLES

The following examples are put forth so as to provide those of ordinaryskill in the art with a complete disclosure and description of how tomake and use the methods and compositions of the invention, and are notintended to limit the scope of what the inventors regard as theirinvention. Efforts have been made to ensure accuracy with respect tonumbers used (e.g., amounts, temperature, etc.), but some experimentalerrors and deviations should be accounted for. Unless indicatedotherwise, parts are parts by weight, temperature is in degreesCentigrade, and pressure is at or near atmospheric. (Figure errorbars=mean±SEM).

Example 1 Effect of Anti-hDll4 Antibody in Combination with Cisplatin

The effect of anti-Dll4 antibody (REGN421) in combination with cisplatin(platinol, cis-diamminedichloroplatinum) on tumor growth was evaluatedon tumors implanted in Severe Combined Immunodeficiency (SCID) miceexpressing a humanized Dll4 protein (humanized Dll4 SCID mice). Thehumanized Dll4 SCID mouse was made by replacing the entire extracellulardomain of the mouse Dll4 gene with the corresponding extracellularregion of the human Dll4 gene (7 kb) in embryonic stem (ES) cells.Homozygous hDll4 mice were generated and bred into SCID background.

Each mouse was implanted subcutaneously (sc) with 1×10⁶ human VM-Cub1tumor cells (bladder carcinoma cells) plus MATRIGEL™ (BD Biosciences,#354234). After the tumors were established in the mice (tumor size of150-200 mm³, approximately 14 days after implantation), tumors weremeasured, randomized and treated with hFc, REGN421, cisplatin, orcombination of REGN421 and cisplatin. A total of 45 mice were dividedinto nine groups (n=5 per cohort). The first group was treatedsubcutaneously (sc) with hFc at 2 mg/kg; the second and third groupswere treated sc with REGN421 at 0.5 and 2 mg/kg, respectively; thefourth and fifth groups were treated intraperitoneally (ip) withcisplatin at 0.5 and 2 mg/kg, respectively; the sixth group was treatedsc with REGN421 at 0.5 mg/kg and ip with cisplatin at 0.5 mg/kg; theseventh group was treated sc with REGN421 at 0.5 mg/kg and ip withcisplatin at 2 mg/kg; the eighth group was treated sc with REGN421 at 2mg/kg and ip with cisplatin at 0.5 mg/kg; and the ninth group wastreated sc with REGN421 at 2 mg/kg and ip with cisplatin at 2 mg/kg.REGN421 was administered every 3-4 days starting on day 14 and micereceived three doses total. Cisplatin was administered every 24 hoursstarting on day 14; mice received four doses total.

To assess the effects of REGN421 and cisplatin as single agents or incombination treatments, the changes in tumor size were recorded. Tumorgrowth was measured three days before the initial REGN421 treatment, onthe day of each REGN421 treatment (days 14, 17 and 21) and thereafterevery 3-4 days until tumors reached ˜600 mm³ in size. In vivo tumor sizewas calculated using the formula (length×width²)/2 (FIG. 1 and Table 1).

TABLE 1 TREATMENT TGI TGD Euthanized (mg/kg/dose) (%) (days) (day) hFc —— 32 REGN421 (0.5) −13.7 0 32 REGN421 (2) 83.1 12 44 Cisplatin (0.5)60.7 13 45 Cisplatin (2) 53.8 9 41 REGN421 (0.5) + cisplatin (0.5) 4.4 234 REGN421 (0.5) + cisplatin (2) −0.8 0 28 REGN421 (2) + cisplatin (0.5)104.8 49 >81 REGN421 (2) + cisplatin (2) 57.9 7 39

Tumor Growth Inhibition, TGI, was determined by calculating thedifference in tumor size for treated (T) versus vehicle control (C)tumor at the day the control cohort was euthanized (i.e., at day 32);TGI=[1−(T_(final)−T_(initial))/(C_(final)−C_(initial))]×100.

Tumor growth delay, TGD, was assessed as the difference in days betweentreated (T) versus control (C) tumors when each cohort reached aspecified tumor size. The predetermined tumor size for this experimentwas 600 mm³.

The results show that treatment with REGN421 alone caused a 54%reduction in tumor growth. Treatment with cisplatin alone resulted inreduced tumor growth (61% reduction for the dose of 0.5 mg/kg/injection;and 54% reduction for the dose of 2 mg/kg/injection). The combinationtreatments produced higher reductions in tumor growth than either singleagent treatment (104% reduction for 0.5 mg/kg/injection cisplatin plus 2mg/kg/injection REGN421; and 58% reduction for 2 mg/kg/injectioncisplatin plus 2 mg/kg/injection REGN421).

These results showed that the treatment of tumors with a combination ofDll4 blocker together with cisplatin, at 2 mg/kg/injection of Dll4blocker and 0.5 mg/kg/injection cisplatin, can result in greaterinhibition of tumor growth than either single agent.

Example 2 Effect of Anti-hDll4 Antibody in Combination with Cisplatin

The effect of REGN421 in combination with cisplatin on tumor growth wasevaluated on tumors implanted in humanized Dll4 SCID mice, as describedabove. Each mouse was implanted subcutaneously (sc) with 5×10⁶ humanA549 tumor cells (non-small cell lung cancer or “NSCLC”). After thetumors were established in the mice (tumor size of 100-150 mm³,approximately 29 days after implantation), tumors were measured,randomized and treated with hFc, REGN421, cisplatin or combination ofREGN421 and cisplatin. A total of 36 mice were divided into 6 groups(n=6 per cohort). The first group was treated sc with hFc at 2 mg/kg;the second group was treated sc with REGN421 at 2 mg/kg; the third andfourth groups were treated ip with cisplatin at 2.5 and 4.5 mg/kg,respectively; the fifth group was treated sc with REGN421 at 2 mg/kg andip with cisplatin at 2.5 mg/kg; and the sixth group was treated sc withREGN421 at 2 mg/kg and ip with cisplatin at 4.5 mg/kg. REGN421 wasadministered every 3-4 days starting on day 29 and mice received threedoses total. Cisplatin was administered every 24 hours starting on day29 and mice received two doses total.

To assess the effects of REGN421 and cisplatin as single agents or incombination we measured tumor size (volume), beginning three days beforethe initial REGN421 treatment, on the day of each agent treatment (days29, 30, 33, 36) and thereafter every 3-4 days until tumors reached ˜600mm³ in size. In vivo tumor size was calculated using the formula(length×width²)/2. The effects on tumor growth are indicated in FIG. 2and Table 2.

TABLE 2 TGI (%) TGD TREATMENT (mg/kg total dose) at Day 57 (days) hFc —— REGN421 2 mg/kg (6) 54 8 Cisplatin 2.5 mg/kg (5) 35 4 Cisplatin 4.5mg/kg (9) 22 11 REGN421 2 mg/kg (6) + Cisplatin 2.5 mg/kg (5) 69 21REGN421 2 mg/kg (6) + Cisplatin 4.5 mg/kg (9) 80 26

The results show that treatment with REGN421 alone caused a 54%reduction in tumor growth. Treatment with cisplatin alone resulted inreduced tumor growth (35% reduction for the dose of 2.5 mg/kg/injection;and 22% reduction for the dose of 4.5 mg/kg/injection). The combinationtreatments produced higher reductions in tumor growth than either singleagent treatment (69% reduction for 2.5 mg/kg/injection of cisplatin plus2 mg/kg/injection of REGN421; and 80% reduction for 4.5 mg/kg/injectionof cisplatin plus 2 mg/kg/injection of REGN421). The combinationtreatments delayed tumor growth significantly (21 days for 2.5mg/kg/injection of cisplatin plus 2 mg/kg/injection of REGN421; and 26days for 4.5 mg/kg/injection of cisplatin plus 2 mg/kg/injection ofREGN421), compared to control and either single agent (p<0.01).

These results show that treatment of tumors with a combination of Dll4blocker together with cisplatin, at 2 mg/kg/injection of Dll4 blockerand 2.5-4.5 mg/kg/injection of cisplatin, can result in greaterinhibition of tumor growth than either single agent.

Example 3 Effect of Anti-hDll4 Antibody in Combination with Docetaxel

The effect of anti-Dll4 antibody in combination with docetaxel(TAXOTERE®) on tumor growth was evaluated on tumors implanted in SevereCombined Immunodeficiency (SCID) mice. Each mouse was implantedsubcutaneously (sc) with 1×10⁶ rat C6 tumor cells (glioblastoma cells).After the tumors were established (tumor size of ˜100-150 mm³,approximately 13 days after implantation), the mice were treated withhFc, docetaxel, Dll4 antibody, or a combination of docetaxel plus Dll4antibody. Since these mice expressed mouse Dll4, the Dll4 Ab used inthis experiment was prepared in-house, based on the published sequence(WO 2007/143689), and designated as REGN 577. REGN 577 binds to humanand mouse Dll4, but does not detectably binds human Dll1 and JAG1. Atotal of 30 tumor-bearing male mice were randomized into six groups(N=5). The first group was treated subcutaneously with hFc (at 25 mg/kg)and intravenously (iv) with vehicle; the second group was treated withREGN577 sc at 5 mg/kg; the third group was treated with docetaxel iv at4.5 mg/kg; the fourth group was treated with docetaxel iv at 6 mg/kg;the fifth group was treated with docetaxel iv at 4.5 mg/kg plus REGN577sc at 5 mg/kg; the sixth group was treated with docetaxel iv at 6 mg/kgplus REGN577 sc at 5 mg/kg. Docetaxel and/or Dll4 antibody wereadministered on the same day. Animals were treated 2 times per week andreceived a total of 3 doses. Starting from the day of initial treatment,body weight and tumors were measured twice a week until the mice wereeuthanized when tumors reached ˜600 mm³ in size. Tumor size wascalculated using the formula, (length×width²)/2.

The control tumors reached the size of ˜600 mm³ and were harvested onday 25. At Day 25, the results show that treatment with Dll4 antibodyalone caused a modest reduction in tumor growth (by approximately 44%).Treatment with docetaxel alone resulted in reduced tumor growth (62%reduction for the dose of 4.5 mg/kg; and 70% reduction for the dose of 6mg/kg). The combination treatments produced larger reductions in tumorgrowth (75% reduction for 4.5 mg/kg docetaxel plus Dll4 Ab; and 81%reduction for 6 mg/kg docetaxel plus Dll4 Ab) than control and eithersingle agent treatment. TGI and TGD were determined (Table 3).

TABLE 3 TGI(%) TGD TREATMENT (mg/kg total dose) at Day 25 (days) REGN5775 mg/kg (15) 44 3 Docetaxel 4.5 mg/kg (13.5) 62 6 Docetaxel 6 mg/kg (18)70 7 REGN577 5 mg/kg (15) + Docetaxel 4.5 mg/kg (13.5) 75 10 REGN577 5mg/kg (15) + Docetaxel 6 mg/kg (18) 81 13

These results show that treatment of tumors with a combination of Dll4blocker together with various doses of docetaxel, can delay tumor growthalmost twice as long and result in greater tumor growth inhibition thaneither single agent.

Example 4 Effect of Anti-hDll4 Antibody in Combination with Docetaxel

The effect of anti-Dll4 antibody in combination with docetaxel(TAXOTERE®, sanofi-aventis) on tumor growth was evaluated on tumorsimplanted in Severe Combined Immunodeficiency (SCID) mice. Each mousewas implanted ‘pseudo-orthotopically’ (subcutaneously into mammary gland#3) with 5×10⁶ human MDA-MB-231 breast tumor cells with MATRIGEL™ (BDBiosciences lot #84540). After the tumors were established in the mice(tumor size of ˜150-200 mm³, approximately 45 days after implantation),mice were treated with hFc, docetaxel, Dll4 antibody, or a combinationof docetaxel plus Dll4 antibody. A total of 25 tumor-bearing male micewere randomized into five groups (N=5 mice per group). The first groupwas treated subcutaneously with hFc (at 25 mg/kg) and intravenously (iv)with vehicle; the second group was treated with Dll4 antibody REGN577 scat 5 mg/kg; the third group was treated with docetaxel iv at 4.5 mg/kg;the fourth group was treated with docetaxel iv at 6 mg/kg; the fifthgroup was treated with docetaxel iv at 6 mg/kg plus REGN577 sc at 5mg/kg. Docetaxel and/or Dll4 antibody were administered on the same day.Animals were treated 2 times per week and received a total of 3 doses.Starting from the day of initial treatment, body weight and tumors weremeasured twice a week until the mice are euthanized. Mice wereeuthanized when tumors reached ˜600 mm³ in size. Tumor size wascalculated using the formula (length×width²)/2.

The control tumors reached ˜600 mm³ and were harvested on day 63. At Day63, the results show that treatment with docetaxel alone produced modestreduction of tumor growth (37% reduction for the dose of 4.5 mg/kg; and52% reduction for the dose of 6 mg/kg). Treatment with Dll4 antibodyalone caused a significant reduction in tumor growth (approximately 85%reduction); meanwhile the combination treatment resulted in tumorregression (105% reduction for 6 mg/kg docetaxel plus Dll4 Ab). TGI andTGD were determined (Table 4).

TABLE 4 TGI(%) TGD TREATMENT (mg/kg total dose) at Day 25 (days) REGN5775 mg/kg (15) 85 21 Docetaxel 4.5 mg/kg (13.5) 37 4 Docetaxel 6 mg/kg(18) 52 4 REGN577 5 mg/kg (15) + Docetaxel 6 mg/kg (18) 105 28

Docetaxel treatment alone resulted in minimal delay in tumor growth (4days for the dose of 4.5 mg/kg; and 4 days for the dose of 6 mg/kg).Tumors treated with Dll4 antibody alone delayed tumor growth by 21 days.The combination treatments delayed tumor growth further, compared tocontrol and either single agent treatment (28 days for 6 mg/kg docetaxelplus Dll4 Ab; p<0.5).

These results show that MDA-MB-231 tumors are modestly responsive todocetaxel treatment alone but are very sensitive to treatment withanti-Dll4 antibody. Combination of Dll4 blocker together with docetaxelcan further delay tumor growth and slightly improve tumor growthinhibition (tumor regression) compared to either single agent.

Example 5 Effect of Anti-hDll4 Antibody in Combination with 5-FU

The effect of anti-Dll4 Ab (REGN421) in combination with 5-FU on tumorgrowth was evaluated on tumors implanted in humanized Dll4 SCID mice.Each mouse was implanted subcutaneously (sc) with 5×10⁶ human HCT116tumor cells (CRC). After the tumors were established in the mice (tumorsize of ˜150 mm³, 22 days after implantation), tumors were measured andrandomized. The mice were then treated with hFc, REGN421, 5-FU orcombination of REGN421 and 5-FU. A total of 30 mice were divided into 6groups (n=5 per cohort). The first group was treated sc with hFc at 2mg/kg; the second group was treated sc with REGN421 at 2 mg/kg; thethird and fourth groups were treated ip with 5-FU at 15 and 25 mg/kg,respectively; the fifth group was treated sc with REGN421 at 2 mg/kg andip with 5-FU at 15 mg/kg; and the sixth group was treated sc withREGN421 at 2 mg/kg and ip with 5-FU at 25 mg/kg. REGN421 wasadministered every 3-4 days starting on day 22 and mice received threedoses total. 5-FU was administered every 3-4 days starting on day 22 andmice received three doses total.

To assess the effects of REGN421 and 5-FU as single agents or incombination, the changes in tumor size (volume) were measured, beginningthree days before the initial REGN421 treatment, and then on the day ofeach agent treatment (days 22, 26, 29) and thereafter every 3-4 daysuntil tumors reach ˜600 mm³ in size. In vivo tumor size is calculatedusing the formula (length×width²)/2 (FIG. 3 and Table 5).

TABLE 5 TGI(%) TGD TREATMENT (mg/kg total dose) at Day 39 (days) REGN4212 mg/kg (6) 36.3 6 5-FU 15 mg/kg (45) 5.6 4 5-FU 25 mg/kg (75) 0 2REGN421 2 mg/kg (6) + 5-FU 15 mg/kg 15 mg/kg (45) 66.8 7 REGN421 2 mg/kg(6) + 5-FU 25 mg/kg (75) 63.3 7

5-FU treatment alone resulted in minimal delay in tumor growth (4 daysfor the total dose of 45 mg/kg; and 2 days for the total dose of 75mg/kg). Tumors treated with Dll4 antibody alone delayed tumor growth by6 days. The combination treatments delayed tumor growth further,compared to control (p<0.043).

Example 6 Effect of Anti-hDll4 Antibody in Combination with Irinotecan

The effect of anti-Dll4 Ab (REGN421) in combination with irinotecan(irinotecan hydrochloride) on tumor growth was evaluated on tumorsimplanted in humanized Dll4 SCID mice.

Each mouse was implanted subcutaneously (sc) with 5×10⁶ human HCT116tumor cells. After the tumors were established in the mice (tumor sizeof ˜150 mm³, 15 days after implantation), tumors were measured andrandomized. The mice were then treated with hFc, REGN421, irinotecan orcombination of REGN421 and irinotecan. A total of 30 mice were dividedinto 6 groups (n=5 per cohort). The first group was treated sc with hFcat 2 mg/kg; the second group was treated sc with REGN421 at 2 mg/kg; thethird and fourth groups were treated ip with irinotecan at 7.5 and 25mg/kg, respectively; the fifth group was treated sc with REGN421 at 2mg/kg and ip with irinotecan at 7.5 mg/kg; and the sixth group wastreated sc with REGN421 at 2 mg/kg and ip with irinotecan at 25 mg/kg.REGN421 was administered every 3-4 days starting on day 15 and micereceived three doses total. Irinotecan was administered every 3-4 daysstarting on day 15 and mice received three doses total.

To assess the effects of REGN421 and irinotecan as single agents or incombination treatments, the changes in tumor size (volume) are measured,starting three days before the initial REGN421 treatment, and then onthe day of each agent treatment (days 15, 19, 22) and thereafter every3-4 days until tumors reach ˜600 mm³ in size. In vivo tumor size iscalculated using the formula (length×width²)/2. Results are shown inFIG. 4 and Table 6.

TABLE 6 TGI(%) TGD TREATMENT (mg/kg total dose) at Day 39 (days) REGN4212 mg/kg (6) 81.3 9 Irinotecan 7.5 mg/kg (22.5) 71.2 8 Irinotecan 25mg/kg (75) 100.5 16 REGN421 2 mg/kg (6) + Irinotecan 7.5 mg/kg (22.5)91.5 10 REGN421 2 mg/kg (6) + Irinotecan 25 mg/kg (75) 119.6 19

Irinotecan treatment alone resulted in delay in tumor growth (8 days forthe total dose of 22.5 mg/kg; and 16 days for the total dose of 75mg/kg). Tumors treated with Dll4 antibody alone delayed tumor growth by9 days. The combination treatments significantly improved anti-tumorefficacy and delayed tumor growth further, compared to either singleagent treatment (19 days for 75 mg/kg irinotecan plus Dll4 Ab;p<0.0001).

Example 7 Effect of Anti-hDll4 Antibody on Hey1 Gene Expression inColo205 Tumor

The effect of anti-hDll4 antibody on differential gene expression intumors was studied in humanized Dll4 SCID mice implanted with humanColo205 colorectal tumor cells. Briefly, Male and female humanized Dll4SCID mice were subcutaneously implanted with 2×10⁶ Colo205 cells permouse. When the tumors reached ˜150 mm³, mice (4 animals per group) weretreated with a single dose of REGN421 at 0.5, 5 or 15 mg/kg, or of hFccontrol at 15 mg/kg. The tumors were excised at 5 hrs, 10 hrs, 24 hrs,72 hrs and 7 days after the treatment and stored in RNA laterstabilization reagent (Qiagen). Tumor RNA was purified using the RNEASY®Midi Kit (Qiagen). Tissue was homogenized in lysis buffer containingβ-mercaptoethanol in a mixer mill, loaded onto the columns and unboundcontaminants washed through. DNase I digestion was performed on thecolumn and RNA was eluted in RNase-free water. Cyanine 3 (Cy3)-CTP wasincorporated into amplified cRNA from 500 ng of total RNA using theQUICK AMP™ RNA Amplification Kit (Agilent Technologies). Cy3-labeledcRNA from each sample was then hybridized to a custom array coveringboth the mouse and human transcriptome. The hybridization and wash ofthe arrays were performed according to the manufacture's protocol andarrays were scanned on an Agilent Microarray scanner. The data wereextracted from scanned array images using the Agilent Feature ExtractionSoftware 9.5.

To identify genes differentially expressed between control and treatmentgroups, per-chip median centering is applied to the complete genomicprofile of each sample. Gene expression values are then compared betweentwo groups using a random variance model t-test (Simon, R. A. et al.,2007, “Analysis of Gene Expression Data Using BRB-Array Tools”, CancerInform 3:11-7). Those genes with a mean difference greater than 1.5-foldand p-value <0.05 between the two groups are selected and rankeddescending fold change. A global test is also performed in which theindividual sample labels are permuted up to 1000 times and the geneselection process is repeated. This determines if the number of genesidentified as differentially expressed between the two groups is morethan would be expected by chance alone.

Hey1 is a member of Hey family that has been identified as immediatedownstream targets of Notch activation and it has been shown thatinhibition of Dll4-Notch pathway signaling in tumors in vivo in micestudies results in the reduction of Hey-1 RNA levels (Noguera-Troise, Iet al., 2006, Nature 444(7122):1032-7). As shown in FIG. 5, analysis ofHey1 mRNA levels in the current study using microarray revealed thatHey1 mRNA levels were decreased in the REGN421-treated mice compared tocontrol hFc-treated mice starting at 10 hours post-treatment, but weremost significantly decreased at 72 hours and 7 days post-treatment. Nosignificant decrease was observed at 0.5 mg/kg, i.e., the lowest dose ofREGN421. These results indicated that REGN421 effectively blocked theNotch signal pathway and that Hey1 could be a useful pharmacodynamicmarker for inhibition of Notch signaling by a Dll4 antibody.

Example 8 Preliminary Pharmacokinetic Study in Phase I

REGN421 is currently being studied in a first-in-human trial. Theprimary objective of the study is to determine the recommended dose ofREGN421 for future efficacy trials. The secondary objectives are tocharacterize the drug safety profile, its pharmacokinetics,immunogenicity, and pharmacodynamics, as well as preliminary evidence ofefficacy. In this study, anti-hDll4 antibody REGN 421 is administeredintravenously every 3 weeks to patients whose cancer has progressed onconventional therapy. The study design follows standard methodology fordose escalation and definition of dose-limiting toxicity. To date, 7patients have been treated at 0.25 mg/kg/dose every three weeks, and 6patients have been treated at 0.50 mg/kg/dose every three weeks. For thepharmacokinetic study, blood samples were taken at pre-dose, 0 hour, andpost-dose 1, 2, 4 and 8 hours on Day 1, followed by Days 2, 3, 4, 8 and15 of Cycle 1; and pre-dose, 0 hour on Day 1 of Cycles≧2, andpost-treatment follow-up on Days 15, 30 and 60. Plasma/serum levels ofREGN421 in the samples are measured by ELISA with an upper limit ofquantification of 2.5 μg/mL and a lower limit of quantification of 0.039μg/mL in the undiluted serum sample. The study is ongoing with theintent to administer higher doses, defined in the protocol as 1, 2, 4,and 7 mg/kg/dose.

The currently available data showing plasma pharmacokinetic parametersfollowing single 30-min. IV infusion of REGN421 at 0.25 mg/kg (7patients) and 0.5 mg/kg (2 patients), are shown in Table 7. C_(max):Maximum serum concentration of the drug; T_(last): Time to the lastquantifiable concentration of the drug; C_(last): Last quantifiableconcentration of the drug; AUC_(last): Area under curve up to the lastconcentration of the drug; AUC: Total area under the curve (i.e., drugexposure); t_(1/2Z): Terminal half life; V_(ss): Volume of distributionat steady state; CL: Drug clearance rate. Values are: mean, (CV %), and[range] (a: median [range]).

TABLE 7 Dose C_(max) T_(last) ^(a) C_(last) AUC_(last) AUC T_(1/2Z)V_(ss) CL (mg/kg) (μg/mL) (h) (μg/mL) (μg * h/mL) (μg * h/mL) (h) (L)(L/h) 0.25 6.27 170 0.51 452 489 47.1 2.85 0.0473 (n = 7) (30.5) [72-240] (57.7)    (56.7) (55.9) (33.5) (27.3)  (39.5)   0.5  9.88 2032.24 759 963 92.3 3.64 0.0355 (n = 2) [9.25-10.5] [73-333] [0.976-3.51][479-1040] [684-1240] [40.6-144] [2.65-4.63] [0.0273-0.0436]

As shown in Table 7, peak serum concentrations of REGN421 were averagevalues of 6.27 μg/mL at the 0.25 mg/kg dose level, and 9.88 μg/mL at the0.50 mg/kg dose level. These values are in the range of REGN421concentrations associated with anti-tumor activity in animal xenograftmodels.

The pharmacodynamic effect of REGN421 on the Dll4-notch signalingpathway has been analyzed using microarray technology on the patientserum samples collected prior to as well as 24 hours following REGN421administration. The results are shown in Table 8.

TABLE 8 Hey-1 transcript Dose Post-treatment vs. Patient (mg/kg)Pre-treatment ratio 1 0.25 0.52 2 0.25 0.85 3 0.25 0.77 4 0.25 0.51 50.25 0.61 6 0.25 0.55 7 0.25 0.75 8 0.5 0.68 9 0.5 0.82

As shown in Table 8, the expression of the Hey-1 gene upon REGN421administration was reduced compared to pre-treatment samples, in allsamples. As observed in the xenograft tumor model in humanized Dll4 SCIDmice (see Example 7 above), the findings suggest that REGN421 is indeedinhibiting the biological activity of Dll4 in humans.

Example 9 Dll4 Ab in Combination with Gemcitabine to Phase I Patients

The study will be conducted in adult patients with advanced ormetastatic cancer that is refractory to standard therapy or have noapproved treatment options. Patients who are diagnosed The study will beconducted in adult patients with advanced or metastatic cancer that isrefractory to standard therapy or have no approved treatment options.Patients who are diagnosed to have advanced solid malignancies accordingto pathological, physical and radiological examination, with an ECOG(Eastern Cooperative Oncology Group) performance status score of 0-2(0-5 scale) and adequate renal, hepatic and hematological laboratoryparameters are eligible for participation in the study. Patients areallowed to receive concurrent supportive care, such as bloodtransfusions and analgesics, during the study. Patients may havereceived prior chemotherapy or biologic therapy for metastatic disease.Patients are assigned in sequential dosing cohorts in a 3+3 design.Three patients will be enrolled at one dose level and, if no doselimiting toxicities (DLT) occur, dose escalation to the next dose levelwill transpire. If 1 of the first 3 patients experiences a DLT, then 3additional patients may be enrolled at that dose level. If 2 of thefirst 3 patients experience a DLT, then that dose level will beconsidered to have excessive toxicity, and 3 additional patients will beenrolled at the previous dose level. Patients will receive Day 1:anti-Dll4 antibody (e.g., REGN421 or REGN281) at 0.25 to 10 mg/kg IVover 30 minutes plus gemcitabine 1250 mg/m² IV infusion over 30 minutesand Day 8: gemcitabine 1250 mg/m² IV infusion over 30 minutes. Thecombination regimen is repeated every 3 weeks until cancer progressionor intolerable toxicity develops.

The primary end point is to assess the safety, tolerability, anddose-limiting toxicities of the anti-Dll4 antibody in combination withgemcitabine and to identify the maximum tolerated dose (MTD) of theanti-Dll4 antibody in combination with gemcitabine in patients withadvanced solid malignancies. The secondary end points include adescription of antitumor activity according to RECIST criteria (byEisenhauer et al., 2009, Eur J Cancer 4 5:228-247), assessment of thepharmacokinetic (PK) profile of the anti-Dll4 antibody when given incombination with gemcitabine and determination of immunogenicity to theanti-Dll4 antibody. Disease remission is evaluated using physicalexamination, radiological methods (X-Ray, Computed Tomography, orMagnetic Resonance Imaging). Adverse events are assessed using theNational Cancer Institute Common Terminology Criteria for Adverse Events(CTCAE v 4.0, available under Cancer Therapy Evaluation Program or CTEPat the National Cancer Institute web site). Serum samples are taken fromthe patients to measure the concentrations of the anti-Dll4 antibody aswell as the presence of possible antibodies against the anti-Dll4antibody.

Example 10 Administration of Dll4 Ab and FOLFOX to CRC Patients

Briefly, adult patients who are diagnosed to have locally advanced ormetastatic colorectal cancer according to pathological, physical andradiological examination, with an ECOG (Eastern Cooperative OncologyGroup) performance status score of 0-2 (0-5 scale) and adequate renal,hepatic and hematological laboratory parameters are eligible forparticipation in the study. Patients are allowed to receive concurrentsupportive care, such as blood transfusions and analgesics, during thestudy. Patients may not have received prior chemotherapy (oranti-angiogenic, or anti EGFR therapy) for metastatic disease; priorsuch therapy for the adjuvant treatment of their disease is allowed, andmust have been completed at least 12 months prior to enrollment on thisstudy. The patients are randomly assigned in a 1:1 ratio to receiveintravenous FOLFOX chemotherapy (Day 1: Oxaliplatin 85 mg/m² IV infusionand leucovorin (folinic acid) 200 mg/m² IV infusion, followed by 5-FU400 mg/m² IV bolus given over 2-4 minutes, followed by 5-FU 600 mg/m² IVas a 22-hour continuous infusion. Day 2: Leucovorin 200 mg/m² IVinfusion, followed by 5-FU 400 mg/m² IV bolus given over 2-4 minutes,followed by 5-FU 600 mg/m² IV infusion as a 22-hour continuous infusion)with bevacizumab (AVASTIN®: Humanized monoclonal Ab against vascularendothelial growth factor (VEGF), Genentech) (Day 1: 10 mg/kg IV) every2 weeks, or an anti-Dll4 antibody (REGN421) at 0.25 to 10 mg/kg IV onday 1, in combination with the previously mentioned treatment. Thetreatment is repeated every 2 weeks until cancer progression orintolerable toxicity develops.

The primary end point is the proportion of patients who have achieved atleast a partial remission (a 30% or more decrease in the sum ofdiameters of identified cancer lesions, according to RECIST criteria (byEisenhauer et al., 2009, supra) and the secondary end points includetime to tumor progression, and overall survival. Disease remission isevaluated using physical examination, radiological methods (X-Ray,Computed Tomography, or Magnetic Resonance Imaging), and theCarcino-Embryonic Antigen (CEA) level measured in serum. Other clinicalparameters, such as adverse events are also assessed, using the NationalCancer Institute Common Terminology Criteria for Adverse Events (CTCAE v4.0, supra). The patients' serum samples are taken to measure the serumconcentrations of the anti Dll4 antibody as well as the presence ofpossible antibodies against the anti-Dll4 antibody.

Example 11 Phase II of Dll4 Ab in Combination with Docetaxel

The study will be conducted in adult patients with advanced inoperableor metastatic breast cancer. They may have failed prior adjuvanttherapy. Patients who are diagnosed to have breast cancer according topathological, physical and radiological examination, with an ECOG(Eastern Cooperative Oncology Group) performance status score of 0-2 (in0-5 scale) and adequate renal, hepatic and hematological laboratoryparameters are eligible for participation in the study. Patients areallowed to receive concurrent supportive care, such as bloodtransfusions and analgesics, during the study. Patients may not havereceived prior chemotherapy or biologic therapy for metastatic disease.A sequential cohort of up to 100 patients will be treated aftersuccessfully passing screening procedures to determine patienteligibility. Patients will receive Day 1: anti-Dll4 antibody (REGN421)at 0.25 to 10 mg/kg IV over 30 minutes plus docetaxel 75 mg/m² IVinfusion over 30 minutes. The combination regimen is repeated every 3weeks until cancer progression or intolerable toxicity develops.

The primary end point is to assess the efficacy of the treatment basedon tumor response rate according to RECIST criteria (by Eisenhauer etal., 2009, Eur J Cancer 4 5:228-247), and time to disease progression.Secondary endpoints will include a description of the safety and of thepharmacokinetic (PK) profile of the anti-Dll4 antibody when given incombination with docetaxel as well as determination of immunogenicity tothe anti-Dll4 antibody. Disease remission is evaluated using physicalexamination, radiological methods (X-Ray, Computed Tomography, orMagnetic Resonance Imaging). Adverse events are assessed using theNational Cancer Institute Common Terminology Criteria for Adverse Events(CTCAE v 4.0, available under Cancer Therapy Evaluation Program or CTEPat the National Cancer Institute web site). Serum samples are taken fromthe patients to measure the concentrations of the anti-Dll4 antibody aswell as the presence of possible antibodies against the anti-Dll4antibody.

Example 12 A Phase II Study of Dll4 Ab with Cisplatin/Gemcitabine

The study will be conducted in adult patients with advanced inoperableor metastatic bladder cancer. Patients who are diagnosed to haveinvasive bladder cancer according to pathological, physical andradiological examination, with an ECOG (Eastern Cooperative OncologyGroup) performance status score of 0-2 (in 0-5 scale) and adequaterenal, hepatic and hematological laboratory parameters are eligible forparticipation in the study. Patients are allowed to receive concurrentsupportive care, such as blood transfusions and analgesics, during thestudy. Patients may not have received prior chemotherapy or biologictherapy for metastatic disease. A sequential cohort of up to 100patients will be treated after successfully passing screening proceduresto determine patient eligibility. Patients will receive anti-Dll4antibody (REGN421) at 0.25 to 10 mg/kg IV over 30 minutes on day 1 plusgemcitabine 1,000 mg/m² over 30 to 60 minutes on days 1, 8, and 15, pluscisplatin 70 mg/m² on day 2. The combination regimen is repeated every 4weeks until cancer progression or intolerable toxicity develops.

The primary end point is to assess the efficacy of the treatment basedon tumor response rate according to RECIST criteria (by Eisenhauer etal., 2009, Eur J Cancer 4 5:228-247), and time to disease progression.Secondary endpoints will include safety profile and a description of thepharmacokinetic (PK) profile of the anti-Dll4 antibody when given incombination with docetaxel and determination of immunogenicity to theanti-Dll4 antibody. Disease remission is evaluated using physicalexamination, radiological methods (X-Ray, Computed Tomography, orMagnetic Resonance Imaging). Adverse events are assessed using theNational Cancer Institute Common Terminology Criteria for Adverse Events(CTCAE v 4.0, available under Cancer Therapy Evaluation Program or CTEPat the National Cancer Institute web site). Serum samples are taken fromthe patients to measure the concentrations of the anti-Dll4 antibody aswell as the presence of possible antibodies against the anti-Dll4antibody.

The invention claimed is:
 1. A method of reducing an amount of achemotherapeutic agent necessary to achieve a therapeutic effect in asubject having a cancer or tumor, comprising administering to thesubject the chemotherapeutic agent in combination with an antibody orantigen-binding fragment thereof that specifically binds to humanDelta-like ligand 4 (hDll4), wherein the antibody or antigen-bindingfragment comprises a heavy chain variable region (HCVR) comprising heavychain CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:22, 24 and26, respectively, and a light chain variable region (LCVR comprisinglight chain CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:30, 32and 34, respectively, and wherein the amount of the chemotherapeuticagent is reduced compared to the amount required for the sametherapeutic effect in the absence of the antibody or antigen-bindingfragment.
 2. The method of claim 1, wherein the antibody orantigen-binding fragment comprises a HCVR/LCVR combination of SEQ IDNO:20/28 or SEQ ID NO:116/118.
 3. The method of claim 1, wherein thechemotherapeutic agent is at least one selected from the groupconsisting of docetaxel, paclitaxel, sorafenib, sunitinib, pazopanib,gemcitabine, cisplatin, 5-FU, folinic acid, oxaliplatin, irinotecan,carboplatin, capecitabine, topotecan, iproplatin, camptothecin,lamellarin D, and pharmaceutically acceptable salts thereof.
 4. Themethod of claim 1, wherein the amount of a chemotherapeutic agentnecessary to achieve the therapeutic effect is reduced by at least 20%.5. The method of claim 4, wherein the amount of a chemotherapeutic agentnecessary to achieve the therapeutic effect is reduced by 30% to 50%.